Company Cash and Cash Equivalents Drop to $41 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 19 2026
0mins
Should l Buy MREO?
As of December 31, 2025, the Company had cash and cash equivalents of $41.0 million, compared to $69.8 million as of December 31, 2024. The Company's expects, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its operating expenses, and capital expenditure requirements into mid-2027. This guidance does not include any potential upfront payments associated with a partnership for alvelestat or business development activity around any of the Company's non-core programs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MREO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MREO
Wall Street analysts forecast MREO stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.329
Low
0.50
Averages
2.08
High
5.00
Current: 0.329
Low
0.50
Averages
2.08
High
5.00
About MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on the development of therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Mereo BioPharma Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Mereo BioPharma Group plc is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: When the market learned that neither program hit its primary endpoint, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact its stock price and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them before April 6, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to protecting investor interests.
See More
Class Action Lawsuit Reminder Against Mereo BioPharma Group plc
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering stock transactions from June 5, 2023, to December 26, 2025.
- False Statements: The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which failed to meet endpoints against placebo or bisphosphonate control groups, misleading investors throughout the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in potential lead plaintiff appointments, emphasizing that one does not need to be a lead plaintiff to partake in recovery, thus providing an opportunity for investors to recover losses.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, serving some of the largest hedge funds and alternative asset managers globally.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Mereo BioPharma, focusing on potential claims from investors who purchased or acquired securities between June 5, 2023, and December 26, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that April 6, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect legal rights.
- Contact Information Provided: Investors who suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with multiple contact options provided to facilitate investor inquiries, reflecting the firm's commitment to client service.
- Potential Impact Assessment: This investigation may negatively affect Mereo BioPharma's stock price and market confidence, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, aiming to recover damages for investors who purchased securities between June 5, 2023, and December 26, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Allegations of False Statements: The complaint alleges that Mereo provided overly optimistic statements to investors while concealing significant adverse facts related to the Phase 3 ORBIT and COSMIC programs, leading to investor misunderstandings about the company's prospects and impacting investment decisions.
- Clinical Trial Failures: The lawsuit points out that Mereo's two critical clinical trials failed to meet primary endpoints, failing to effectively reduce annualized clinical fracture rates compared to placebo or bisphosphonate control groups, which could severely impact the company's future market performance.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by April 6, 2026, indicating that the legal team will provide risk-free legal support for investors, emphasizing the importance of protecting investor rights and interests.
See More
Reminder for Mereo BioPharma Class Action Participation
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the Phase 3 Orbit and COSMIC studies, claiming setrusumab would significantly reduce annualized fracture rates, while the studies failed to meet primary endpoints, leading investors to purchase ADS at inflated prices.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to carefully select qualified legal counsel, avoiding inexperienced intermediaries, to ensure effective legal representation and support in the class action process.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc should note that the deadline to join the class action for American Depositary Shares purchased between June 5, 2023, and December 26, 2025, is April 6, 2026, and failure to act may result in losing the opportunity to serve as lead plaintiff.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby minimizing the financial risk associated with joining the class action.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma provided misleading positive statements regarding the Phase 3 Orbit and COSMIC studies for setrusumab, leading investors to purchase shares at artificially inflated prices, which ultimately resulted in financial losses when the true results were disclosed, highlighting significant deficiencies in the company's information disclosure practices.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has a proven track record, having recovered over $438 million for investors in 2019 alone, indicating their substantial experience and capability in handling such cases, which is crucial for investors when selecting legal representation.
See More
Mereo BioPharma Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors that Mereo BioPharma Group plc is facing a class action lawsuit for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between June 5, 2023, and December 26, 2025.
- False Statements Exposed: The complaint alleges that Mereo concealed negative facts about its Phase 3 ORBIT and COSMIC programs, rendering its public statements false and materially misleading throughout the class period.
- Investor Losses: When the market learned that neither program hit its primary endpoint, investors suffered damages, indicating significant deficiencies in the company's disclosure practices that could impact its stock price and investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them before April 6, 2026, to participate in the lawsuit and discuss their rights, demonstrating a commitment to protecting investor interests.
See More
Class Action Lawsuit Reminder Against Mereo BioPharma Group plc
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Mereo BioPharma Group plc for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering stock transactions from June 5, 2023, to December 26, 2025.
- False Statements: The complaint alleges that Mereo made false and misleading statements regarding its Phase 3 ORBIT and COSMIC programs, which failed to meet endpoints against placebo or bisphosphonate control groups, misleading investors throughout the class period.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in potential lead plaintiff appointments, emphasizing that one does not need to be a lead plaintiff to partake in recovery, thus providing an opportunity for investors to recover losses.
- Legal Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through balanced counseling and aggressive advocacy, serving some of the largest hedge funds and alternative asset managers globally.
See More
Faruqi & Faruqi Investigates Mereo BioPharma for Investor Losses
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating Mereo BioPharma, focusing on potential claims from investors who purchased or acquired securities between June 5, 2023, and December 26, 2025, indicating possible legal risks for the company.
- Investor Rights Reminder: The firm reminds investors that April 6, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect legal rights.
- Contact Information Provided: Investors who suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly, with multiple contact options provided to facilitate investor inquiries, reflecting the firm's commitment to client service.
- Potential Impact Assessment: This investigation may negatively affect Mereo BioPharma's stock price and market confidence, prompting investors to monitor developments closely to adjust their investment strategies accordingly.
See More
Class Action Filed Against Mereo BioPharma Group plc for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Mereo BioPharma Group plc, aiming to recover damages for investors who purchased securities between June 5, 2023, and December 26, 2025, highlighting significant investor concerns regarding the company's financial transparency.
- Allegations of False Statements: The complaint alleges that Mereo provided overly optimistic statements to investors while concealing significant adverse facts related to the Phase 3 ORBIT and COSMIC programs, leading to investor misunderstandings about the company's prospects and impacting investment decisions.
- Clinical Trial Failures: The lawsuit points out that Mereo's two critical clinical trials failed to meet primary endpoints, failing to effectively reduce annualized clinical fracture rates compared to placebo or bisphosphonate control groups, which could severely impact the company's future market performance.
- Investor Rights Protection: Investors are encouraged to apply to be lead plaintiffs by April 6, 2026, indicating that the legal team will provide risk-free legal support for investors, emphasizing the importance of protecting investor rights and interests.
See More
Reminder for Mereo BioPharma Class Action Participation
- Class Action Notice: Rosen Law Firm reminds investors who purchased Mereo BioPharma ADS between June 5, 2023, and December 26, 2025, to apply as lead plaintiffs by April 6, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that defendants provided false and misleading information regarding the Phase 3 Orbit and COSMIC studies, claiming setrusumab would significantly reduce annualized fracture rates, while the studies failed to meet primary endpoints, leading investors to purchase ADS at inflated prices.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Investor Advisory: Investors are advised to carefully select qualified legal counsel, avoiding inexperienced intermediaries, to ensure effective legal representation and support in the class action process.
See More
Class Action Notice for Mereo BioPharma Investors
- Class Action Deadline: Investors in Mereo BioPharma Group plc should note that the deadline to join the class action for American Depositary Shares purchased between June 5, 2023, and December 26, 2025, is April 6, 2026, and failure to act may result in losing the opportunity to serve as lead plaintiff.
- Fee Arrangement: Investors participating in the lawsuit will not incur any out-of-pocket expenses, as attorney fees will be covered through a contingency fee arrangement, thereby minimizing the financial risk associated with joining the class action.
- Lawsuit Background: The lawsuit alleges that Mereo BioPharma provided misleading positive statements regarding the Phase 3 Orbit and COSMIC studies for setrusumab, leading investors to purchase shares at artificially inflated prices, which ultimately resulted in financial losses when the true results were disclosed, highlighting significant deficiencies in the company's information disclosure practices.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has a proven track record, having recovered over $438 million for investors in 2019 alone, indicating their substantial experience and capability in handling such cases, which is crucial for investors when selecting legal representation.
See More
